Natixis Advisors, L.P. Abb Vie Inc. Transaction History

Natixis Advisors, L.P.

$43.5 Billion
Q1 2024

A detailed history of Natixis Advisors, L.P. transactions in Abb Vie Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 1,088,410 shares of ABBV stock, worth $187 Million. This represents 0.46% of its overall portfolio holdings.

Number of Shares

1,088,410

Previous 996,425 9.23%

Holding current value

$187 Million

Previous $154 Million 28.35%

% of portfolio

0.46%

Previous 0.41%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 25, 2024	BUY	$159.82 - $182.1 $14.7 Million - $16.8 Million	91,985 Added 9.23%	1,088,410 $198 Million
Q4 2023 Feb 06, 2024	BUY	$137.6 - $154.97 $12.6 Million - $14.2 Million	91,525 Added 10.11%	996,425 $154 Million
Q3 2023 Nov 13, 2023	BUY	$133.59 - $154.65 $36.5 Million - $42.3 Million	273,282 Added 43.27%	904,900 $135 Million
Q2 2023 Aug 15, 2023	SELL	$132.51 - $164.9 $13.9 Million - $17.3 Million	-105,179 Reduced 14.28%	631,618 $85.1 Million
Q1 2023 May 11, 2023	BUY	$144.61 - $166.54 $8.41 Million - $9.68 Million	58,125 Added 8.56%	736,797 $117 Million

Q4 2022 Jan 27, 2023	BUY	$138.31 - $165.87 $1.95 Million - $2.34 Million	14,112 Added 2.12%	678,672 $110 Million
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $11.9 Million - $13.6 Million	88,312 Added 15.33%	664,560 $89.2 Million
Q2 2022 Aug 12, 2022	SELL	$137.62 - $174.96 $3.51 Million - $4.46 Million	-25,472 Reduced 4.23%	576,248 $88.3 Million
Q1 2022 May 12, 2022	BUY	$131.98 - $163.75 $9.84 Million - $12.2 Million	74,571 Added 14.15%	601,720 $97.5 Million
Q4 2021 Feb 08, 2022	BUY	$107.43 - $135.93 $6.67 Million - $8.44 Million	62,096 Added 13.35%	527,149 $71.4 Million
Q3 2021 Nov 15, 2021	SELL	$106.4 - $120.78 $711,496 - $807,655	-6,687 Reduced 1.42%	465,053 $50.2 Million
Q2 2021 Aug 12, 2021	BUY	$105.21 - $117.21 $5.01 Million - $5.58 Million	47,609 Added 11.23%	471,740 $53.1 Million
Q1 2021 May 05, 2021	BUY	$102.3 - $112.62 $4.33 Million - $4.77 Million	42,342 Added 11.09%	424,131 $45.9 Million
Q4 2020 Feb 12, 2021	SELL	$80.49 - $108.67 $5.84 Million - $7.88 Million	-72,528 Reduced 15.96%	381,789 $40.9 Million
Q3 2020 Nov 12, 2020	SELL	$85.91 - $100.83 $14.1 Million - $16.5 Million	-163,891 Reduced 26.51%	454,317 $39.8 Million
Q2 2020 Aug 11, 2020	BUY	$73.37 - $98.18 $4.03 Million - $5.4 Million	54,980 Added 9.76%	618,208 $60.7 Million
Q1 2020 Apr 27, 2020	SELL	$64.5 - $97.79 $8.99 Million - $13.6 Million	-139,441 Reduced 19.84%	563,228 $42.9 Million
Q4 2019 Feb 10, 2020	BUY	$72.13 - $90.25 $2.19 Million - $2.74 Million	30,407 Added 4.52%	702,669 $62.2 Million
Q3 2019 Nov 12, 2019	BUY	$62.98 - $75.72 $6.23 Million - $7.49 Million	98,891 Added 17.25%	672,262 $50.9 Million
Q2 2019 Aug 12, 2019	BUY	$65.7 - $83.98 $9.37 Million - $12 Million	142,676 Added 33.13%	573,371 $41.7 Million
Q1 2019 May 15, 2019	BUY	$77.14 - $90.79 $341,575 - $402,018	4,428 Added 1.04%	430,695 $34.7 Million
Q4 2018 Feb 13, 2019	BUY	$77.85 - $96.01 $15.8 Million - $19.5 Million	203,246 Added 91.13%	426,267 $39.3 Million
Q3 2018 Nov 13, 2018	SELL	$88.91 - $98.84 $1.48 Million - $1.65 Million	-16,684 Reduced 6.96%	223,021 $21.1 Million
Q2 2018 Aug 14, 2018	SELL	$89.78 - $106.23 $25,317 - $29,956	-282 Reduced 0.12%	239,705 $0
Q1 2018 May 10, 2018	BUY	$92.01 - $123.21 $365,095 - $488,897	3,968 Added 1.68%	239,987 $22.7 Million
Q4 2017 Feb 14, 2018	SELL	$89.56 - $98.21 $2.53 Million - $2.78 Million	-28,279 Reduced 10.7%	236,019 $22.8 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $18.5 Million - $23.6 Million	264,298	264,298 $23.5 Million

Others Institutions Holding ABBV

# of Institutions

3,651

Shares Held

1.24B

Call Options Held

15.5M

Put Options Held

11.6M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $303B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.

Account

Natixis Advisors, L.P. Abb Vie Inc. Transaction History